It has been widely held that tumor blood vessels, characterized by aberrant structure and function, play a pivotal role in generating an immunosuppressive tumor microenvironment (TME) by restricting the infiltration and function of immune cells. Aggravated immunosuppressive TME also results in excessive and abnormal blood vessel formation. To this end, tumor angiogenesis and immune suppressive microenvironment tend to form positive feedback involving the interactions between tumor endothelial cells and suppressive immune cells, which implicates that enhancement in one side is inclined to augment the other’s effects. Manipulation of immune-vascular crosstalk has been demonstrated to exert striking effects on governing the progression of solid tumors. On one hand, pruning the excessive angiogenesis or normalizing tumor blood vessels is capable of conferring immune reprogramming. On the other hand, immunotherapy potentially functions to yield vascular normalization, which in turn further improves the effectiveness of immunotherapy. More importantly, the combination therapy of anti-angiogenesis and immune checkpoint blockade has been validated to achieve therapeutic benefits in both pre-clinical and clinical settings. Therefore, optimizing the therapeutic strategies of manipulating immune-vascular crosstalk brings great hope for the treatment of cancer patients.
The goal of this research topic is to provide a forum to advance research on the contribution of unveiling the underlying mechanisms of immune-vascular crosstalk formation in solid tumors as well as to explore innovative vasculature-oriented or immune-oriented pharmacological interventions in the attempt to achieve beneficial impacts on tumor progression.
The research topic on “manipulation of immune-vascular crosstalk in solid tumors” will focus on understanding how tumor blood vessels govern immunosuppressive microenvironment as well as investigating how immune reprogramming influences tumor vasculature. We welcome Original Research, Review, Clinical Trial, and Case Report articles concentrating on, but not limited to, the following bullet points:
1) Immune-vascular crosstalk;
2) Interactions between vascular normalization and immune reprogramming;
3) Immunotherapy influences tumor blood vessels;
4) Vascular control of immune subsets in solid tumors;
5) Vascular mimicry in tumors;
6) Novel therapeutic strategies for pruning or normalizing tumor blood vessels;
7) Tumor blood vessel biomarkers for revealing immunotherapy response and cancer prognosis;
8) Clinical trials of combination therapy of anti-angiogenesis and immunotherapy in cancer patients.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
It has been widely held that tumor blood vessels, characterized by aberrant structure and function, play a pivotal role in generating an immunosuppressive tumor microenvironment (TME) by restricting the infiltration and function of immune cells. Aggravated immunosuppressive TME also results in excessive and abnormal blood vessel formation. To this end, tumor angiogenesis and immune suppressive microenvironment tend to form positive feedback involving the interactions between tumor endothelial cells and suppressive immune cells, which implicates that enhancement in one side is inclined to augment the other’s effects. Manipulation of immune-vascular crosstalk has been demonstrated to exert striking effects on governing the progression of solid tumors. On one hand, pruning the excessive angiogenesis or normalizing tumor blood vessels is capable of conferring immune reprogramming. On the other hand, immunotherapy potentially functions to yield vascular normalization, which in turn further improves the effectiveness of immunotherapy. More importantly, the combination therapy of anti-angiogenesis and immune checkpoint blockade has been validated to achieve therapeutic benefits in both pre-clinical and clinical settings. Therefore, optimizing the therapeutic strategies of manipulating immune-vascular crosstalk brings great hope for the treatment of cancer patients.
The goal of this research topic is to provide a forum to advance research on the contribution of unveiling the underlying mechanisms of immune-vascular crosstalk formation in solid tumors as well as to explore innovative vasculature-oriented or immune-oriented pharmacological interventions in the attempt to achieve beneficial impacts on tumor progression.
The research topic on “manipulation of immune-vascular crosstalk in solid tumors” will focus on understanding how tumor blood vessels govern immunosuppressive microenvironment as well as investigating how immune reprogramming influences tumor vasculature. We welcome Original Research, Review, Clinical Trial, and Case Report articles concentrating on, but not limited to, the following bullet points:
1) Immune-vascular crosstalk;
2) Interactions between vascular normalization and immune reprogramming;
3) Immunotherapy influences tumor blood vessels;
4) Vascular control of immune subsets in solid tumors;
5) Vascular mimicry in tumors;
6) Novel therapeutic strategies for pruning or normalizing tumor blood vessels;
7) Tumor blood vessel biomarkers for revealing immunotherapy response and cancer prognosis;
8) Clinical trials of combination therapy of anti-angiogenesis and immunotherapy in cancer patients.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
